Gerresheimer's Strategic Overhaul Following SDAX Delisting

Pharma packager Gerresheimer faces SDAX delisting after accounting scandal, €240M impairments, US plant closure, and credit default negotiations.

The pharmaceutical packaging specialist Gerresheimer finds itself navigating a profound corporate crisis. Its removal from Germany's SDAX index at the end of March, triggered automatically by the Deutsche Börse due to a missing audited annual report for 2025, is merely the most visible symptom. The situation has placed the company in a precarious position with its lenders, forcing management to implement severe structural measures to stabilize its finances.

Accounting Irregularities Halt Financial Reporting

At the heart of Gerresheimer's troubles are systematic accounting errors. Revenue from "bill-and-hold" agreements was recognized prematurely, requiring a substantial restatement. For 2024 alone, the company had to correct its revenue figures downward by €35 million. The scope of the issue has widened, with audit firms KPMG and Grant Thornton now jointly examining the balance sheets for the past two fiscal years.

The financial repercussions of this cleanup are significant. For 2025, the group anticipates non-cash impairment charges of up to €240 million, primarily related to technology projects and its US operations. The absence of a certified financial statement has placed Gerresheimer in technical default on its credit agreements. Management is currently engaged in intense negotiations to secure deadline extensions and prevent the termination of its credit facilities. Consequently, both the annual shareholder meeting and quarterly financial releases have been postponed indefinitely.

Operational Restructuring: Plant Closure and Divestment

In response to the mounting pressure, the executive board is accelerating a major operational restructuring. Its US manufacturing footprint is being substantially reduced. The Moulded-Glass production facility in Chicago Heights is slated for closure by the end of 2026, with capacity shifting to existing plants in Italy and India.

Simultaneously, the company has put its US subsidiary, Centor Inc., up for sale. Centor, which specializes in packaging for prescription drugs, is being marketed by the investment bank Morgan Stanley, with a transaction targeted for completion within the current year. This division was carried on the books at a value of €292 million as of the end of 2024.

A Divided Investor Base

The capital market is reacting to this complex scenario in divergent ways. Gerresheimer's share price has plummeted approximately 72% over a one-year period. This severely depressed valuation is attracting new institutional investors, including Deka Investment and the CastleKnight Master Fund, who are building positions.

On the other hand, shareholder advocacy group DSW is exploring potential legal avenues. With the assistance of an expert legal opinion, it is examining claims for damages against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner.

A Critical Deadline Looms

All forward-looking plans, including a revenue projection targeting up to €2.4 billion, are explicitly contingent on two factors: successful outcomes from bank negotiations and ongoing investigations by the German financial regulator, BaFin. The company faces a pivotal deadline in June. By then, management must present the long-awaited audited annual report and concurrently finalize agreements with its lenders to secure its ongoing financial foundation. The coming weeks will be decisive for Gerresheimer's future trajectory.